Dr. Frances E. Broyles, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
515 Minor Ave, Ste 300
Seattle, WA 98104
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2005
Licensed in Washington since 1990, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
WA license MD00027695 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 25 payments worth $2,684 in total to this clinician.
| Eli Lilly and Company | $2,627 |
|---|---|
| Abbott Laboratories | $21.92 |
| Insulet Corporation | $19.80 |
| Corcept Therapeutics | $15.21 |
| Travel and Lodging | $2,271 |
|---|---|
| Food and Beverage | $413 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $506 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $405 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $324 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $269 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, WA · in-kind | $234 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $184 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $148 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $74.00 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $56.00 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $31.97 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $506 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $405 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $324 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $269 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, WA · in-kind | $234 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $184 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $148 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $74.00 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $56.00 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $31.97 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $12.10 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $11.50 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $5.74 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $4.32 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $2.69 |
| Eli Lilly and Company May 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $2.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 5 companies. The companies reported $2,424,564 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company · Active, not recruiting · NCT06643728 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of tirzepatide once weekly compared to placebo in adult participants with type 1 diabetes a…
Eli Lilly and Company - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Abbott Laboratories - A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company · Completed · NCT05882045
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.